Rosai-Dorfman 病市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型（經典 Rosai-Dorfman 病、結外 Rosai-Dorfman 病）、按手術類型、按最終用戶、按地區和競爭進行細分，2020 年至 2030 年預測

2024 年全球羅賽-多夫曼病 (RDD) 市場價值為 6.4705 億美元，預計到 2030 年將達到 9.6266 億美元，預測期內的年複合成長率(CAGR) 為 6.82%。這個市場代表了醫療保健行業一個專業但至關重要的領域，專注於羅賽-多夫曼病（一種罕見的非惡性疾病，也稱為伴有巨大淋巴結腫大的竇組織細胞增生症 (SHML)）的診斷、治療和持續研究。

RDD 的特徵是組織細胞（一種白血球）過度增殖和積聚，主要發生在淋巴結內，但也可能影響其他組織和器官。儘管其罕見，但全球意識的增強、診斷技術的進步以及對有效治療策略的追求加速了市場的成長。

關鍵促進因素

發病率上升和診斷進展

儘管羅塞-多夫曼病仍然是一種罕見疾病，據估計在美國每 20 萬人中就有 1 人患有此病，每年報告的新病例約為 100 例，但診斷能力的提高已導致全球對該疾病的識別率提高。影像技術、組織病理學和分子診斷方面的創新提高了 RDD 診斷的準確性和及時性，從而增加了報告病例的數量並推動了對有針對性的治療干預的需求。

這種日益成長的認知推動了旨在創造專門診斷工具和治療方法的研究和開發活動。最近的發現，包括在選定的 RDD 患者中發現 BRAF-V600E 等基因突變，為精準醫療和個人化治療策略開闢了新的機會。因此，製藥公司和醫療保健提供者正在投資專門針對 RDD 的臨床和生物學特徵的治療方法。

該市場涵蓋廣泛的產品，包括診斷檢測、影像系統、藥物和支持性護理解決方案。製藥公司、學術機構和臨床服務提供者之間的合作對於推進研究、揭示疾病機制、探索潛在生物標記和開發創新治療方法至關重要。

主要挑戰

疾病盛行率低且認知度有限

市場發展的一大障礙是 RDD 的盛行率極低，加上醫療專業人員的認知有限。由於該疾病的罕見性，常常導致誤診或延遲診斷，因為其臨床表現可能與其他更常見的疾病相似。 RDD 可表現出多種症狀，從無症狀淋巴結腫大到廣泛的器官受累，這進一步增加了及時檢測的難度。

臨床上很少遇到 RDD，導致醫生對此普遍不熟悉，從而妨礙了及時準確的診斷。此外，缺乏廣泛的認知會影響對 RDD 特定研究的資金和投資，從而限制診斷和治療創新的進步。這種投資不足對有效、有針對性的干涉措施的發展提出了挑戰，並阻礙了對該疾病病理生理學的更廣泛理解。

主要市場趨勢

採用免疫組織化學及分子分析

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球羅賽-多夫曼病市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（經典（結節性）Rosai-Dorfman 病、結外 Rosai-Dorfman 病）
  • 依手術類型（診斷、治療）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美Rosai-Dorfman病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲Rosai-Dorfman病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區 Rosai-Dorfman 病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美羅賽-多夫曼病市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲Rosai-Dorfman病市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Koninklijke Philips NV
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

第 16 章：策略建議

第17章調查會社について,免責事項

Global Rosai-Dorfman Disease (RDD) market was valued at USD 647.05 million in 2024 and is projected to reach USD 962.66 million by 2030, expanding at a compound annual growth rate (CAGR) of 6.82% over the forecast period. This market represents a specialized yet vital segment of the healthcare industry, focusing on the diagnosis, treatment, and ongoing research of Rosai-Dorfman Disease-a rare, non-malignant disorder also known as sinus histiocytosis with massive lymphadenopathy (SHML).

RDD is characterized by the excessive proliferation and accumulation of histiocytes-a type of white blood cell-primarily within lymph nodes, though it may also affect other tissues and organs. Despite its rarity, growing global awareness, advancements in diagnostic technologies, and the pursuit of effective treatment strategies have accelerated market growth.

Key Drivers

Rising Incidence and Diagnostic Advancements

While Rosai-Dorfman Disease remains an uncommon condition-with an estimated prevalence of 1 in 200,000 individuals and approximately 100 new cases reported annually in the United States-enhanced diagnostic capabilities have led to increased identification of the disease globally. Innovations in imaging techniques, histopathology, and molecular diagnostics have improved the accuracy and timeliness of RDD diagnoses, contributing to a higher reported case volume and driving demand for targeted therapeutic interventions.

This growing recognition has fueled research and development activities aimed at creating specialized diagnostic tools and treatments. Recent discoveries, including the identification of genetic mutations such as BRAF-V600E in select RDD patients, have opened new opportunities for precision medicine and personalized treatment strategies. As a result, pharmaceutical firms and healthcare providers are investing in therapies tailored specifically to the clinical and biological characteristics of RDD.

The market spans a broad range of offerings including diagnostic assays, imaging systems, pharmaceuticals, and supportive care solutions. Collaborative efforts among pharmaceutical companies, academic institutions, and clinical providers are crucial in advancing research, uncovering disease mechanisms, exploring potential biomarkers, and developing innovative treatments.

Key Challenges

Low Disease Prevalence and Limited Awareness

A significant barrier to market development is the exceptionally low prevalence of RDD, compounded by limited awareness among healthcare professionals. The rarity of the condition often leads to misdiagnosis or delayed diagnosis, as its clinical presentation may mimic other, more common diseases. RDD can manifest with a wide spectrum of symptoms, from asymptomatic lymph node enlargement to extensive organ involvement, further complicating timely detection.

Infrequent clinical encounters with RDD contribute to a general unfamiliarity among physicians, hindering prompt and accurate diagnosis. Additionally, the lack of widespread awareness impacts funding and investment in RDD-specific research, limiting advancements in diagnostic and therapeutic innovations. This underinvestment challenges the development of effective, targeted interventions and impedes the broader understanding of the disease's pathophysiology.

Key Market Trends

Adoption of Immunohistochemistry and Molecular Profiling

The market is witnessing a paradigm shift toward precision diagnostics, underscored by the increasing use of immunohistochemistry (IHC) and molecular profiling. These technologies are becoming standard in identifying and confirming RDD cases with greater accuracy. IHC techniques enable the detection of disease-specific protein markers such as S100 and CD68, facilitating differentiation from other histiocytic and lymphoproliferative disorders.

Simultaneously, molecular profiling-through platforms such as next-generation sequencing (NGS)-is uncovering recurrent mutations (e.g., KRAS, MAP2K1) associated with RDD pathogenesis. These insights are paving the way for personalized therapeutic approaches, particularly for patients with refractory or recurrent disease.

As molecular diagnostic tools become more accessible and cost-effective, their adoption is expanding across both developed and emerging healthcare markets. Institutions are integrating these technologies into clinical practice, not only improving diagnostic precision but also enhancing patient monitoring and prognosis assessment.

Key Market Players

• Koninklijke Philips N.V.
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

Report Scope:

In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Rosai-Dorfman Disease Market, By Type:

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

Global Rosai-Dorfman Disease Market, By Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Global Rosai-Dorfman Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Global Rosai-Dorfman Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.

Available Customizations:

Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rosai-Dorfman Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
  • 5.2.2. By Procedure Type (Diagnosis, Treatment)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Rosai-Dorfman Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Procedure Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rosai-Dorfman Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Rosai-Dorfman Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Rosai-Dorfman Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure Type
      • 6.3.3.2.3. By End User

7. Europe Rosai-Dorfman Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Procedure Type
  • 7.2.3. By End User
  • 7.2.4. By Age Group
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Rosai-Dorfman Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Rosai-Dorfman Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Rosai-Dorfman Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Procedure Type
  • 8.2.3. By End User
  • 8.2.4. By Age Group
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Rosai-Dorfman Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Rosai-Dorfman Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Rosai-Dorfman Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Rosai-Dorfman Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure Type
      • 8.3.5.2.3. By End User

9. South America Rosai-Dorfman Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Procedure Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Rosai-Dorfman Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Rosai-Dorfman Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Rosai-Dorfman Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Rosai-Dorfman Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Procedure Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Rosai-Dorfman Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Rosai-Dorfman Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Rosai-Dorfman Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Koninklijke Philips N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. GE HealthCare
• 15.3. Canon Inc
• 15.4. Siemens Healthineers
• 15.5. SternMed GmbH
• 15.6. Jubilant Cadista Pharmaceuticals Inc
• 15.7. LGM Pharma
• 15.8. Henan Lihua Pharmaceutical Co., Ltd
• 15.9. Niksan Pharmaceutical
• 15.10. Sandoz Canada Inc

16. Strategic Recommendations

17. About Us & Disclaimer